Michele Basso, Carlo Signorelli, Maria Alessandra Calegari, Jessica Lucchetti, Ina Valeria Zurlo, Emanuela Dell'Aquila, Giulia Arrivi, Federica Zoratto, Fiorenza Santamaria, Rosa Saltarelli, Giovanni Trovato, Giulia Caira, Lorenzo Angotti, Marta Schirripa, Annunziato Anghelone, Francesco Schietroma, Mario Giovanni Chilelli, Lisa Salvatore, Carmelo Pozzo, Giampaolo Tortora
BACKGROUND: There are few molecular markers driving treatment selection in later lines of treatment for advanced colorectal cancer patients. The vast majority of patients who progress after first- and second-line therapy undergo chemotherapy regardless of molecular data. OBJECTIVE: We aimed to assess the prognostic and predictive effects of specific RAS mutations on overall survival of patients receiving regorafenib (rego), trifluridine/tipiracil (TFD/TPI), or both...
April 13, 2024: Targeted Oncology